Skip to main
PODD

Insulet (PODD) Stock Forecast & Price Target

Insulet (PODD) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 38%
Buy 19%
Hold 38%
Sell 5%
Strong Sell 0%

Bulls say

Insulet is poised for long-term success due to its innovative products, strong brand recognition, and expanding international presence, but recent challenges in retaining and utilizing customers within the Type 2 diabetes population have led to a cautious outlook. While the company is taking steps to address these issues, it may take some time before the effects are seen in financials. However, strong growth potential and a relatively attractive valuation make Insulet an interesting prospect for investors looking for a long-term investment in the healthcare industry.

Bears say

Insulet is facing many challenges that could potentially impact the company's profitability and growth. These challenges include cybersecurity threats, increased competition in the insulin pump market, supply chain and manufacturing risks, potential disruptions from GLP-1 RA and multi-agonist therapies, and regulatory and reimbursement shifts. The company also faces risks from intellectual property and patent litigation. Additionally, while Insulet has a strong new user adoption rate, the company's declining drug delivery revenue and uncertainty around its 2027 outlook could limit further growth potential in the near future. Overall, these factors contribute to a negative outlook on the company's stock.

Insulet (PODD) has been analyzed by 21 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 19% recommend Buy, 38% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insulet (PODD) Forecast

Analysts have given Insulet (PODD) a Buy based on their latest research and market trends.

According to 21 analysts, Insulet (PODD) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $193.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $193.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insulet (PODD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.